Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology

Pei Ning Wang; Kun Ju Lin; Huei Chun Liu; Ulf Andreasson; Kaj Blennow; Henrik Zetterberg; Shieh Yueh Yang

doi:10.1002/dad2.12029

Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology

Pei Ning Wang, Kun Ju Lin, Huei Chun Liu, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Shieh Yueh Yang^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Introduction: Pyroglutamate-modified amyloid β (Aβ_pE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting Aβ_pE3-40. Methods: Immunomagnetic reduction was used for quantification of Aβ_pE3-40 in plasma from 46 participants. The concentrations of Aβ_pE3-40 of these subjects were compared with ¹⁸F-florbetapir positron emission tomography (PET) images. Results: Aβ_pE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of Aβ_pE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of Aβ_pE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using Aβ_pE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.

Original language	English
Article number	e12029
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	12
Issue number	1
DOIs	https://doi.org/10.1002/dad2.12029
Publication status	Published - 2020
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/dad2.12029

Cite this

@article{96535e80ee924c8f983fdc7c29886815,

title = "Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology",

abstract = "Introduction: Pyroglutamate-modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting AβpE3-40. Methods: Immunomagnetic reduction was used for quantification of AβpE3-40 in plasma from 46 participants. The concentrations of AβpE3-40 of these subjects were compared with 18F-florbetapir positron emission tomography (PET) images. Results: AβpE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of AβpE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of AβpE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using AβpE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.",

author = "Wang, {Pei Ning} and Lin, {Kun Ju} and Liu, {Huei Chun} and Ulf Andreasson and Kaj Blennow and Henrik Zetterberg and Yang, {Shieh Yueh}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association.",

year = "2020",

doi = "10.1002/dad2.12029",

language = "English",

volume = "12",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology

AU - Wang, Pei Ning

AU - Lin, Kun Ju

AU - Liu, Huei Chun

AU - Andreasson, Ulf

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Yang, Shieh Yueh

PY - 2020

Y1 - 2020

N2 - Introduction: Pyroglutamate-modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting AβpE3-40. Methods: Immunomagnetic reduction was used for quantification of AβpE3-40 in plasma from 46 participants. The concentrations of AβpE3-40 of these subjects were compared with 18F-florbetapir positron emission tomography (PET) images. Results: AβpE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of AβpE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of AβpE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using AβpE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.

AB - Introduction: Pyroglutamate-modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting AβpE3-40. Methods: Immunomagnetic reduction was used for quantification of AβpE3-40 in plasma from 46 participants. The concentrations of AβpE3-40 of these subjects were compared with 18F-florbetapir positron emission tomography (PET) images. Results: AβpE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of AβpE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of AβpE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using AβpE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.

UR - http://www.scopus.com/inward/record.url?scp=85089341101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089341101&partnerID=8YFLogxK

U2 - 10.1002/dad2.12029

DO - 10.1002/dad2.12029

M3 - Article

AN - SCOPUS:85089341101

SN - 2352-8729

VL - 12

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

M1 - e12029

ER -

Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this